GlassScriptPhysician profile
Barry I Rosenblum
NPI 1932148962
$42,832.78
in general payments reported to CMS, 2019-2025
26 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,723 · 2021: $5,552 · 2022: $21K · 2023: $232 · 2024: $3,400 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,413 · Travel and Lodging: $997 · Long Term Medical Supply Or Device Loan: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,413.00 |
| Travel and Lodging | $997.49 |
| Long Term Medical Supply Or Device Loan | $293.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $31,067.54 | 2019-2024 | Affinity, Puraply Wound Matrix, Nushield |
| Integra Lifesciences Corporation | $4,176.49 | 2019-2025 | Micromatrix, Integra, Primatrix |
| Osiris Therapeutics INC. | $1,832.64 | 2019 | |
| Inari Medical, INC. | $1,481.20 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kairos Surgical INC | $1,236.82 | 2022-2023 | |
| Smith+Nephew, INC. | $1,203.40 | 2019-2025 | Grafix Pl, Stravix |
| Lifenet Health | $384.85 | 2024-2025 | Theragenesis Wound Matrix |
| Stryker Corporation | $352.67 | 2020-2022 | |
| Kci USA, INC. | $250.00 | 2020 | |
| Kerecis Limited | $117.71 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Advanced Oxygen Therapy INC. | $103.86 | 2023-2024 | Topical Oxygen Chamber For Extremities, Topical Oxygen Chamber For Extremities |
| Derma Sciences, INC. | $102.71 | 2019 | |
| Medical Device Business Services, INC. | $69.60 | 2022 | |
| Medline Industries LP | $68.36 | 2020 | |
| Misonix INC | $54.13 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $52.76 | 2024 | Qutenza |
| Biocomposites INC | $45.88 | 2023-2024 | Stimulan |
| Medartis INC. | $42.50 | 2020-2021 | |
| Medela LLC | $36.32 | 2019 | |
| Melinta Therapeutics, LLC | $32.27 | 2019 | |
| Polynovo North America LLC | $30.10 | 2024 | Novosorb Btm |
| Bioventus LLC | $23.94 | 2023 | |
| Arthrosurface Incorporated | $20.12 | 2019 | |
| Aroa Biosurgery Incorporated | $18.31 | 2019 | |
| Bone Support INC. | $14.77 | 2024 | Ceramentbone Void Filler, Cerament G |
| Orthofix Medical, INC. | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Rosenblum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.